MAIA Biotechnology (MAIA) Fundamental Analysis: Revenue, Earnings & Valuation

2.63 / 10

Underperform

Fundamental rating is Underperform with a 2.6/10 score. Strengths include interest coverage and revenue‑to‑market value; weaknesses are high current‑liabilities ratio and poor PB‑ROE. Overall outlook remains guarded.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight71.48%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.98%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-8.15%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value79.64

Score1/3

Weight-11.41%

1M Return-1.69%

PB-ROE

Value3.58

Score0/3

Weight24.08%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.39

Score3/3

Weight6.25%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-8.28%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.40%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-7.83%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight32.48%

1M Return4.00%

Is MAIA undervalued or overvalued?

MAIA scores 2.63/10 on fundamentals and holds a Premium valuation at present. Backed by its -745.24% ROE, 0.00% net margin, -3.55 P/E ratio, 33.45 P/B ratio, and 33.33% earnings growth, these metrics solidify its Underperform investment rating.